Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 6/20 | 0.58 |
| ▸ | KDR | P35968 | 3/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | ATR | Q13535 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956512 | 0.87 | TGFBR1 (0.59) | TGFBR1KDRMAPK14ATRGABRA5 | |
| SCHEMBL5956479 | 0.83 | TGFBR1 (0.57) | TGFBR1KDRMAPK14ATRGABRA5 | |
| SCHEMBL5956425 | 0.81 | HPGD (0.52) | TGFBR1ABL1 | |
| SCHEMBL5907452 | 0.81 | HDAC1 (0.50) | TGFBR1HDAC6ROCK2ROCK1KDM1A | |
| SCHEMBL5907501 | 0.78 | HDAC1 (0.47) | TGFBR1KDM1A | |
| SCHEMBL6231313 | 0.77 | RAB9A (0.46) | — | |
| SCHEMBL24307575 | 0.76 | TGFBR1 (0.55) | TGFBR1KDRMAPK14ATRGABRA5 | |
| SCHEMBL5907457 | 0.76 | KDM1A (0.38) | TGFBR1KDRMAPK14HDAC6ABL1 | |
| SCHEMBL5907494 | 0.76 | FKBP1A (0.52) | — | |
| SCHEMBL5907453 | 0.75 | TGFBR1 (0.69) | TGFBR1KDRMAPK14ATRGABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058329-A1 | Pyrazole inhibitors of the transforming growth factor | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | disclosed |
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058329-A1 | Pyrazole inhibitors of the transforming growth factor | SMAD3, SMAD2, TGFBR1 | TGFBR1 3/4885KDR 228/4885MAPK14 148/4885 |
| US-20060004051-A1 | Compounds | SMAD3, SMAD2, TGFBR1 | TGFBR1 3/4885KDR 227/4885MAPK14 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.